share_log

Clearmind Medicine | UPLOAD: Others

Clearmind Medicine | UPLOAD: Others

Clearmind Medicine | UPLOAD:其他
SEC announcement ·  02/14 22:16
Moomoo AI 已提取核心訊息
Clearmind Medicine Inc., a biotechnology company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-1, filed on February 7, 2024, will not undergo review by the commission. The SEC's communication, dated February 14, 2024, was addressed to Dr. Adi Zuloff-Shani, the Chief Executive Officer of Clearmind Medicine. The SEC also reminded the company of its responsibility for the accuracy and adequacy of disclosures, irrespective of the SEC's review process. Clearmind Medicine was directed to Rules 460 and 461 should they wish to request acceleration of the registration process. The SEC provided contact information for further inquiries, directing them to Cindy Polynice.
Clearmind Medicine Inc., a biotechnology company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-1, filed on February 7, 2024, will not undergo review by the commission. The SEC's communication, dated February 14, 2024, was addressed to Dr. Adi Zuloff-Shani, the Chief Executive Officer of Clearmind Medicine. The SEC also reminded the company of its responsibility for the accuracy and adequacy of disclosures, irrespective of the SEC's review process. Clearmind Medicine was directed to Rules 460 and 461 should they wish to request acceleration of the registration process. The SEC provided contact information for further inquiries, directing them to Cindy Polynice.
美國證券交易委員會(SEC)已告知生物技術公司Clearmind Medicine Inc.,其於2024年2月7日提交的F-1表格註冊聲明不會經過該委員會的審查。美國證券交易委員會於2024年2月14日發給了Clearmind Medicine首席執行官阿迪·祖洛夫-沙尼博士。美國證券交易委員會還提醒該公司,無論美國證券交易委員會的審查程序如何,其對披露的準確性和充分性負有責任。如果Clearmind Medicine希望申請加快註冊程序,則應遵循第460和461條。美國證券交易委員會提供了進一步調查的聯繫信息,並將其定向到辛迪·波利尼斯。
美國證券交易委員會(SEC)已告知生物技術公司Clearmind Medicine Inc.,其於2024年2月7日提交的F-1表格註冊聲明不會經過該委員會的審查。美國證券交易委員會於2024年2月14日發給了Clearmind Medicine首席執行官阿迪·祖洛夫-沙尼博士。美國證券交易委員會還提醒該公司,無論美國證券交易委員會的審查程序如何,其對披露的準確性和充分性負有責任。如果Clearmind Medicine希望申請加快註冊程序,則應遵循第460和461條。美國證券交易委員會提供了進一步調查的聯繫信息,並將其定向到辛迪·波利尼斯。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息